Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phototoxicity Study of MC2-01 Cream (Wynzora) in Healthy Subjects
NCT03892564Phase 1Completed
- Sponsor
- MC2 Therapeutics
- Start
- Feb 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of calcipotriol + betamethasone in plaque psoriasis (5 arms), sponsored by MC2 Therapeutics. Primary endpoint: Evaluator Rating of Possible Dermal Reactions (Erythema, Edema and Other Signs of Cutaneous Irritation). Started Feb 2019; status: completed.
02
Drugs
calcipotriol + betamethasone
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03892564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892564.